CA50588/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1990	1
1992	1
1993	4
1994	2
1995	7
1996	4
1997	3
1998	5
1999	3
2000	6
2001	1
2002	1
2010	2
2011	1
2024	0

1

Regulation of apoptosis in prostatic disease.

Thompson TC, Yang G. Thompson TC, et al. Prostate Suppl. 2000;9:25-8. doi: 10.1002/1097-0045(2000)45:9+<25::aid-pros6>3.0.co;2-5. Prostate Suppl. 2000. PMID: 11056499 Review.

2

Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential.

Thompson TC. Thompson TC. Yonsei Med J. 2010 Jul;51(4):479-83. doi: 10.3349/ymj.2010.51.4.479. Yonsei Med J. 2010. PMID: 20499410 Free PMC article. Review.

3

Transforming growth factor beta 1 as a biomarker for prostate cancer.

Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Thompson TC, et al. J Cell Biochem Suppl. 1992;16H:54-61. doi: 10.1002/jcb.240501212. J Cell Biochem Suppl. 1992. PMID: 1289674 Review.

4

Metastasis-related genes in prostate cancer: the role of caveolin-1.

Thompson TC. Thompson TC. Cancer Metastasis Rev. 1998-1999;17(4):439-42. doi: 10.1023/a:1006110326366. Cancer Metastasis Rev. 1998. PMID: 10453288 Review.

5

In situ gene therapy for prostate cancer: immunomodulatory approaches.

Thompson TC, Timme TL, Ebara S, Satoh T, Yang G, Wang J, Miles BJ, Ayala G, Wheeler TM, Kadmon D. Thompson TC, et al. Expert Opin Biol Ther. 2001 May;1(3):481-95. doi: 10.1517/14712598.1.3.481. Expert Opin Biol Ther. 2001. PMID: 11727520 Review.

6

Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth.

Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC. Timme TL, et al. Microsc Res Tech. 1995 Mar 1;30(4):333-41. doi: 10.1002/jemt.1070300408. Microsc Res Tech. 1995. PMID: 7541677 Review.

7

Transgenic models for the study of prostate cancer.

Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Thompson TC, et al. Cancer. 1993 Feb 1;71(3 Suppl):1165-71. doi: 10.1002/1097-0142(19930201)71:3+<1165::aid-cncr2820711440>3.0.co;2-u. Cancer. 1993. PMID: 8428340 Review.

8

Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease.

Thompson TC, Timme TL, Park SH, Yang G, Ren C. Thompson TC, et al. Prostate. 2000 Jun 1;43(4):248-54. doi: 10.1002/1097-0045(20000601)43:4<248::aid-pros3>3.0.co;2-p. Prostate. 2000. PMID: 10861743 Review.

9

Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes.

Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Langeberg WJ, et al. Prostate. 2010 Jun 15;70(9):1020-35. doi: 10.1002/pros.21137. Prostate. 2010. PMID: 20209490 Free PMC article.

10

Effects of genetic background on tumorigenesis in p53-deficient mice.

Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr, Park SH, Thompson T, Ford RJ, Bradley A. Donehower LA, et al. Mol Carcinog. 1995 Sep;14(1):16-22. doi: 10.1002/mc.2940140105. Mol Carcinog. 1995. PMID: 7546219

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

41 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year